A Pilot Study of ALTENS in Improving Dysphagia Induced by IMRT for Head and Neck Cancers
1. oktober 2012 oppdatert av: Raimond Wong, McMaster University
Effectiveness of Acupuncture-like Transcutaneous Nerve Stimulation (ALTENS) in Improving Dysphagia and Associated Symptoms of Chemotherapy and/or Intensity Modulated Radiation Therapy (IMRT) for Head and Neck Cancers: A Pilot Study
Study hypothesis: ALTENS techniques, administered within the first 3 months after radiation completion, can improve radiation-induced dysphagia and associated symptoms in head and neck cancer patients. This beneficial effect is mediated by the reduction of chronic inflammatory response of swallowing musculature to radiation, consequently a reduction in muscle fibrosis.
Primary study objective: To evaluate the effectiveness of ALTENS in relieving radiation-induced dysphagia. Eating Assessment Tool (EAT-10) scores will be used for this primary study endpoint.
Studieoversikt
Detaljert beskrivelse
Difficulty in swallowing is a concerning symptom after radiation treatment for some types of head and neck cancers.
Swallowing becomes difficult when radiation damage induces inflammation (with swelling and pain) in the inner covering tissues of the throat and muscles that involve in the swallowing process.
Currently, supportive measures are used to manage this symptom while waiting for the tissue damages to heal.
In some patients, the inflamed muscles develop scar tissues causing long-term swallowing difficulty and narrowing of the swallowing passage.
Needle acupuncture may help to reduce tissue inflammation and may lessen the severity of swallowing difficulty.
However, needle puncture is often not desired by patients.
Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) is like acupuncture treatment, but the acupuncture points are stimulated with mild electrical stimulation without needles, simplifying treatment delivery.
This study is to examine if a pre-selected set of acupuncture points treated using ALTENS can reduce swallowing difficulty.
There will be a total of 12 treatments given over 6 to 8 weeks.
Changes in severity of swallowing difficult after treatment will be assessed using 2 subjective assessment tools.
Studietype
Intervensjonell
Registrering (Forventet)
35
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V5C2
- Juravinski Cancer Centre
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:This study will recruit patients with head and neck cancers treated with radiation+/- chemotherapy and who meet the following criteria (EAT-10 assessment will be used for screening):
Inclusion Criteria
- present with dysphagia symptoms
- with no evidence of residue cancer
- are within 3 months (but past 1 month) after treatment completion
- show positive dysphagia (EAT-10 score of > 3) and/ or aspiration on barium swallow study
- are over 18 years old
- are able to read and write fluent English
- can give informed consent
Exclusion Criteria:
- have unstable heart disease
- have infectious disease transmissible by blood or body fluid, including hepatitis and HIV
- have skin disease at site of study acupuncture points that prevents the application of electrodes
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ALTENS
Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
|
ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment.
Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Subjective Dysphagia Assessment Score: EAT-10 from baseline
Tidsramme: 3 months after treatment completion
|
EAT-10 is a self-administered questionnaire for subjective assessment of dysphagia.
It consists of 10 items and each item is scored using a 5-point Likert scale.
The higher the point, the more severe the problem being scored.
Normative data suggested that a total score of 3 or higher is abnormal.
|
3 months after treatment completion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in M. D. Anderson dysphagia inventory from baseline
Tidsramme: 3 months after treatment completion
|
M. D. Anderson dysphagia inventory (MDADI) is a self-administered questionnaire designed specifically to assess the quality of life for head and neck cancer patients who suffer from dysphagia.
It incorporated three domains: emotional, functional and physical, and one global question.
There are a total of 20 items.Each item is scored on a scale of 1 to 5 with 1 being strongly agree and 5 strongly disagree except for two items, one on the emotional subscale and the other on the functional subscale.
The global question is scored and interpreted separately.
The scores of all the items in each domain are summed and a mean score is calculated.
The final score for each subscale is calculated by multiplying the calculated mean score by 20 with a final range from 0 to 100.
The final score of the global question is also calculated in the same way.
The higher the final score represents better functioning and quality of life.
|
3 months after treatment completion
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Raimond Wong, MD, McMaster University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. oktober 2012
Primær fullføring (Forventet)
1. september 2013
Studiet fullført (Forventet)
1. desember 2013
Datoer for studieregistrering
Først innsendt
26. september 2012
Først innsendt som oppfylte QC-kriteriene
1. oktober 2012
Først lagt ut (Anslag)
2. oktober 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
2. oktober 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. oktober 2012
Sist bekreftet
1. oktober 2012
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MU12-530
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .